Decapeptide Combi-Therapy: A New Approach for Steroid-Resistant Cancers
Steroid-related cancers have the highest incidence among tumors and its market potential for Europe and U.S.A. is estimated to be at least US$ 2.4 bn p.a. Scientists at the University of Göttingen developed novel proprietary decapeptidic antagonists to target GnRH-II receptor (which is highly expressed in steroidal cancers like e.g. breast, ovarian, endometrium and prostate carcinomas), which could be used in a combination cancer therapy and which potentially could also be used to treat malignant melanoma.
Further Information: PDF
MBM ScienceBridge GmbH
Phone: (0551) 30724-151
Contact
Dr. Jens-Peter Horst
